End-To-End RBM Strategies for Effective Clinical Trials
Comprehensive risk-based monitoring (RBM) strategies and technology are vital to the success of your clinical trial. We also support your study by making sure your strategy meet RBM functional requirements as outlined in part two of TransCelerate Biopharma’s RBM Technology Considerations. Our cross-functional teams evaluate your study protocol to further identify risks using our Risk Assessment Categorization Tool (RACT), and integration into Pharm-Olam's leading bow tie risk management system.
A holistic, end-to-end RBM strategy needs the right technology to support it. Pharm-Olam leverages Medidata's Rave Clinical Cloud to power our clinical execution and RBM strategies. Medidata's Rave Clinical Cloud leads the industry, it captures data from a all study data sources such as EDC, eDiaries, central laboratories, imaging documents and brings it into one unified platform for data aggregation and analysis.
From start to close, our clinical operations team works with you to ensure the RBM strategy for your study is fully able to identify and manage risks and provide the highest data integrity. To learn more about how Pharm-Olam is Powered by Medidata, click link below.